Clinical Pharmacists’ Knowledge of and Attitudes toward Pharmacogenomic Testing in China
暂无分享,去创建一个
Christine Y. Lu | Luwen Shi | Xin-yi Zhang | Sicong Li | T. Jia | Xiaowen Hu | Xiaoyan Nie | Caiying Wu | Jing Chen | Yuqing Zhang
[1] Christine Y. Lu,et al. Clinical Pharmacists’ Involvement in Pharmacogenomics Testing and Related Services in China , 2022, Journal of personalized medicine.
[2] M. Young,et al. Pharmacogenomic testing: perception of clinical utility, enablers and barriers to adoption in Australian hospitals , 2022, Internal medicine journal.
[3] J. Hoffman,et al. ASHP Statement on the Pharmacist's Role in Clinical Pharmacogenomics. , 2021, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.
[4] Weimin Cai,et al. A Survey of Pharmacogenomics Testing Among Physicians, Pharmacists, and Researchers From China , 2021, Frontiers in Pharmacology.
[5] T. Mushiroda,et al. Results of a nationwide survey of Japanese pharmacists regarding the application of pharmacogenomic testing in precision medicine , 2021, Journal of clinical pharmacy and therapeutics.
[6] Thikryat Neamatallah,et al. Knowledge, perception, and confidence of hospital pharmacists toward pharmacogenetics in Jeddah, Kingdom of Saudi Arabia , 2020, Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society.
[7] M. Nijenhuis,et al. Pharmacogenetics Guidelines: Overview and Comparison of the DPWG, CPIC, CPNDS, and RNPGx Guidelines , 2021, Frontiers in Pharmacology.
[8] I. Jang,et al. Pharmacogenomic information from CPIC and DPWG guidelines and its application on drug labels , 2020, Translational and clinical pharmacology.
[9] C. Aquilante,et al. Assessment of healthcare professionals' knowledge, attitudes, and perceived challenges of clinical pharmacogenetic testing in Egypt. , 2020, Personalized medicine.
[10] Yuankai Huang,et al. The current status of pharmaceutical care provision in tertiary hospitals: results of a cross-sectional survey in China , 2020, BMC Health Services Research.
[11] Kun Wang,et al. Mental Health and Psychosocial Problems of Medical Health Workers during the COVID-19 Epidemic in China , 2020, Psychotherapy and Psychosomatics.
[12] D. Liang,et al. Social Support and User Characteristics in Online Diabetes Communities: An In-Depth Survey of a Large-Scale Chinese Population , 2020, International journal of environmental research and public health.
[13] C. Pisanu,et al. Challenges and Future Prospects of Precision Medicine in Psychiatry , 2020, Pharmacogenomics and personalized medicine.
[14] S. Mahasirimongkol,et al. Knowledge, attitude, and practice towards pharmacogenomics among hospital pharmacists in Thailand , 2020, Pharmacogenetics and genomics.
[15] K. Alzoubi,et al. Physicians’ Attitudes and Ethical Obligations to Pharmacogenetic Testing , 2020, Journal of multidisciplinary healthcare.
[16] Yanting Wang,et al. Opportunities for pharmacists to integrate pharmacogenomics into clinical practice , 2019, The Pharmacogenomics Journal.
[17] I. Cascorbi,et al. Implementation and obstacles of pharmacogenetics in clinical practice: An international survey , 2019, British journal of clinical pharmacology.
[18] A. Awad,et al. Knowledge, perceptions and confidence of physicians and pharmacists towards pharmacogenetics practice in Kuwait , 2018, PloS one.
[19] Henk-Jan Guchelaar,et al. A nationwide survey of pharmacists' perception of pharmacogenetics in the context of a clinical decision support system containing pharmacogenetics dosing recommendations. , 2017, Pharmacogenomics.
[20] A. Serretti,et al. Progress and prospects in pharmacogenetics of antidepressant drugs , 2016, Expert opinion on drug metabolism & toxicology.
[21] Alaa M Althubaiti,et al. Information bias in health research: definition, pitfalls, and adjustment methods , 2016, Journal of multidisciplinary healthcare.
[22] F. Collins,et al. A new initiative on precision medicine. , 2015, The New England journal of medicine.
[23] M. Z. Salleh,et al. Pharmacogenomics Based Practice in Malaysia: The Attitude, Knowledge and Adoption by the Healthcare Professionals , 2020 .
[24] B. Bernhardt,et al. Community pharmacists' attitudes towards clinical utility and ethical implications of pharmacogenetic testing. , 2013, Personalized medicine.
[25] T. Hurlimann,et al. An evaluation of pharmacists' expectations towards pharmacogenomics. , 2013, Pharmacogenomics.
[26] S. Sadhasivam,et al. Pharmacogenomics of opioids and perioperative pain management. , 2012, Pharmacogenomics.
[27] W Burke,et al. Primary care physicians' knowledge of and experience with pharmacogenetic testing , 2012, Clinical genetics.
[28] T. McMahon,et al. The perceptions of pharmacists in Victoria, Australia on pharmacogenetics and its implications , 2011, Pharmacy practice.
[29] F. Ashbury,et al. Personalised medicine in Canada: a survey of adoption and practice in oncology, cardiology and family medicine , 2011, BMJ Open.
[30] M. Rudis,et al. Assessment of the Pharmacogenomics Educational Needs of Pharmacists , 2011, American Journal of Pharmaceutical Education.
[31] Jiang Xue-hua,et al. Survey on Hospital Pharmaceutical Care in China and the Status Quo of Clinical Pharmacy Practice(Part 2):Survey on Status Quo of Clinical Pharmacy Practice , 2009 .
[32] R. Cacabelos. Pharmacogenomics and therapeutic prospects in dementia , 2008, European Archives of Psychiatry and Clinical Neuroscience.
[33] W. Newman,et al. Patients' and healthcare professionals' views on pharmacogenetic testing and its future delivery in the NHS. , 2007, Pharmacogenomics.
[34] C. Szoeke,et al. Update on pharmacogenetics in epilepsy: a brief review , 2006, The Lancet Neurology.
[35] H. McLeod,et al. Pharmacogenetics in rheumatology: the prospects and limitations of an emerging field. , 2002, Rheumatology.
[36] C. Hepler,et al. Opportunities and responsibilities in pharmaceutical care. , 1990, American journal of hospital pharmacy.